News | Radiopharmaceuticals and Tracers | July 12, 2016

Arrangement with Institute for Radioelements will ensure supply of radiopharmaceutical for lung imaging beyond October

Lantheus, Xenon 133 gas, radiopharmaceuticals, IRE, Institute for Radioelements Belgium

July 12, 2016 — Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the first commercial shipment of Xenon Xe 133 gas (Xenon 133) using unprocessed radiochemical Xenon 133 supplied by the Institute for Radioelements (IRE) in Belgium.

Xenon 133 is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs.

Earlier this month, Lantheus received approval from the U.S. Food and Drug Administration (FDA) for IRE to be a supplier of unprocessed radiochemical Xenon 133 for processing and finishing by Lantheus. IRE’s supply will supplement and eventually replace Lantheus’ current Xenon 133 supply when the National Research Universal (NRU) reactor in Canada no longer provides a regular supply of medical isotopes to the marketplace in October 2016.

For more information: www.lantheus.com

Related Content

News | Lung Imaging

November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 ...

Time November 23, 2021
arrow
News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
News | Artificial Intelligence

November 22, 2021 — Sirona Medical, a software company founded on a deep understanding of both the practice and business ...

Time November 22, 2021
arrow
News | Coronavirus (COVID-19)

November 22, 2021 — Lung autopsy and plasma samples from people who died of COVID-19 have provided a clearer picture of ...

Time November 22, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | X-Ray

November 19, 2021 — “Data drive decisions and with the latest trial data, we are positioned for growth,” said Amol ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 ...

Time November 18, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — VIDA Diagnostics Inc. (VIDA) is further removing friction in respiratory clinical trials with the ...

Time November 18, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
Subscribe Now